Track the Inhibrx, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Health Care sector, Inhibrx, Inc. has logged 30 reports. Market capitalisation: €1.5bn. The latest transaction was reported on 3 June 2024 (J). Among the most active insiders: Eckelman Brendan P.. Every trade is accessible without an account.
30
Insider Decl.
0
Thresholds
€40m
2 ops.
Buy Volume
€191m
23 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Inhibrx, Inc. Buy (bullish), based on 2 analysts. Average price target: US$277.50.
37Σ signal
Buys €40m€191m Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.